LGB-321 HCl, with the CAS number 1210416-93-5, is a chemical compound that belongs to the class of small molecule inhibitors. It is primarily recognized for its role as a selective inhibitor of certain protein kinases, particularly those involved in cancer cell signaling pathways. The hydrochloride salt form, indicated by "HCl," enhances its solubility in aqueous solutions, making it suitable for various biological assays and therapeutic applications. LGB-321 has been studied for its potential in treating specific types of cancers, particularly those characterized by aberrant signaling through the targeted kinases. Its mechanism of action typically involves the inhibition of kinase activity, which can lead to reduced cell proliferation and increased apoptosis in cancer cells. As with many pharmacological agents, the compound's efficacy and safety profile are evaluated through preclinical and clinical studies, focusing on its pharmacokinetics, pharmacodynamics, and potential side effects. Overall, LGB-321 HCl represents a promising avenue in cancer therapeutics, contributing to the ongoing development of targeted cancer treatments.

LGB-321 is a potent and selective ATP-competitive small molecule inhibitor of PIM kinases (Pan-PIM kinase inhibitor). LGB321 is unique relative to previously described PIM inhibitors, in that it is active in PIM2 dependent cell lines. , a kinase that has proven difficult to inhibit in the cellular context. Consistent with its activity on all three PIM kinases, LGB321 inhibits proliferation of a number of cell lines derived from diverse hematological malignancies, including MM, AML, CML and B-Cell NHL. In vivo, LGB-321 is orally available, demonstrates efficacy in tumor xenografts and is well-tolerated within the therapeutic exposure range in mice. (source: Clin Cancer Res. 2014 Apr 1;20(7):1834-45 )

LGB-321 HCl

1210416-93-5: LGB-321 HCl, with the CAS number 1210416-93-5, is a chemical compound that belongs to the class of small molecule inhibitors. It is primarily recognized for its role as a selective inhibitor of certain protein kinases, particularly those involved in cancer cell signaling pathways. The hydrochloride salt form, indicated by "HCl," enhances its solubility in aqueous solutions, making it suitable for various biological assays and therapeutic applications. LGB-321 has been studied for its potential in treating specific types of cancers, particularly those characterized by aberrant signaling through the targeted kinases. Its mechanism of action typically involves the inhibition of kinase activity, which can lead to reduced cell proliferation and increased apoptosis in cancer cells. As with many pharmacological agents, the compound's efficacy and safety profile are evaluated through preclinical and clinical studies, focusing on its pharmacokinetics, pharmacodynamics, and potential side effects. Overall, LGB-321 HCl represents a promising avenue in cancer therapeutics, contributing to the ongoing development of targeted cancer treatments.

LGB-321: potent, selective PIM kinase inhibitor, active against PIM2, halts diverse blood cancers' growth, orally effective in mice.

CAS 1210416-93-5

LGB-321 HCl

LGB-321 HCl

Ref: TM-T71227